An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

UPTRAVI®

Drug Information Related Patent

Hold Company

ACTELION

Learn More

Dosage and Administration

POWDER;INTRAVENOUS

Specification

1.8MG/VIAL

Indication

UPTRAVI® is suitable for the treatment of pulmonary hypertension, slow down disease progression and reduce the risk of hospitalization for PAH.

Use

Instructions for Use

API

SELEXIPAG

API Structure

We Supply

SELEXIPAG

Note:

Facility GMP
USMF

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
7205302	2026/10/31
8791122	2030/8/1
9173881	2029/8/12
9284280	2030/6/25

API Patent

Patent No	Expiration Date
7205302	2026/10/31

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION